BrainChip’s first-to-market neuromorphic processor IP, Akida™, mimics the human brain to analyze only essential sensor inputs at the point of acquisition, .
Nano Artificial Nose used to test for COVID-19 BrainChip, a specialist in high performance artificial intelligence technology, has announced progress in testing with the NaNose (Nano Artificial Nose) where patientsâ exhaled breath samples were tested for COVID-19.
The NaNose Medical technology is based on the artificial nose developed at the Technion Israel Institute of Technology, which has the same sensitivity to minute quantities of Volatile Organic Compounds (VOCs) as a dogâs nose.
It has been used in tests since 2017 to identify diseases including Parkinson s, cancers, kidney failure, multiple sclerosis and infectious diseases such as COVID-19.
NaNose Medical collected samples from 130 patients and sent nanomaterial sensor data to BrainChipâs Research Institute in Perth, Western Australia, which configured and trained its Akida neuromorphic processor to interpret the data using AI/ML.